Interv Akut Kardiol. 2018;17(1):42-43

Three-year clinical outcomes of the ABSORB III trial

Milan Plíva

Kardiologické centrum Agel, Pardubice

Interní klinika, kardiologické oddělení, Nemocnice Pardubice

ABSORB III, a prospective, randomized, multicenter trial, evaluated the safety and efficacy of the Absorb® (Abbott, USA) everolimus-eluting poly-L-lactic acid based bioresorbable vascular scaffold (BVS) compared to the Xience® (Abbott, USA) everolimus-elutingcobalt-chromium stent (DES) during one year after implantation. One-year occurrence of the primary endpoint a composite ofcardiac death, target vessel myocardial infarction, and ischemia-driven target lesion revascularization) demonstrated noninferiorityof BVS compared to DES, however with a tendency to higher rates of adverse events in the BVS group. Three-year follow–upresults demonstrated an additional increase in adverse events occurence which was statistically, significant with respect to scaffoldthrombosis and target vessel myocardial infarction in the BVS group.

Keywords: BVS, Absorb BVS, PCI, DES, scaffold thrombosis

Published: April 1, 2018  Show citation